Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-005389
Filing Date
2025-01-13
Accepted
2025-01-13 17:27:19
Documents
14

Document Format Files

Seq Description Document Type Size
1 DEFA14A d896317ddefa14a.htm DEFA14A 168267
2 GRAPHIC g896317dsp1.jpg GRAPHIC 4905
3 GRAPHIC g896317ex2p10g1.jpg GRAPHIC 288322
4 GRAPHIC g896317ex2p11g1.jpg GRAPHIC 514263
5 GRAPHIC g896317ex2p1g1.jpg GRAPHIC 178918
6 GRAPHIC g896317ex2p2g1.jpg GRAPHIC 281491
7 GRAPHIC g896317ex2p3g1.jpg GRAPHIC 366054
8 GRAPHIC g896317ex2p4g1.jpg GRAPHIC 308415
9 GRAPHIC g896317ex2p5g1.jpg GRAPHIC 350545
10 GRAPHIC g896317ex2p6g1.jpg GRAPHIC 318297
11 GRAPHIC g896317ex2p7g1.jpg GRAPHIC 134661
12 GRAPHIC g896317ex2p8g1.jpg GRAPHIC 223738
13 GRAPHIC g896317ex2p9g1.jpg GRAPHIC 181729
14 GRAPHIC g896317g0114004153274.jpg GRAPHIC 56162
  Complete submission text file 0001193125-25-005389.txt   4588894
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36274 | Film No.: 25527143
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)